m6A-centered Drug Response Information
General Information of the Drug (ID: M6APDG00567)
Name |
Erythromycin stearate
|
||||
---|---|---|---|---|---|
Synonyms |
Eratrex; Erypar; Erythrocin stearate; Erythromycin octadecanoate (salt); Erythromycin stearate (salt); Erythromycin stearate [BAN:JAN]; Erythromycin steraric acid salt; Erythromycin, stearate (salt); Ethril; Ethril 250; Gallimycin; HSDB 4178; LXW024X05M; Meberyt; NCI-C55674; OE 7; Octadecanoic acid, compd. with erythromycin (1:1); Pfizer-E; Qidmycin; Stearic acid, compd. with erythromycin (1:1); UNII-LXW024X05M; Wyamycin S; Erycen; Erycette; Erycin; Erycinum; Eryderm; Erygel; Erymax; Erythra-Derm; Erythro-Statin; Erythrocin; Erythromycin; Erythrogran; Erythroguent; Erythromid; Erythromycin A; Erythromycin base; Erythromycine; Erythromycinum; Ilocaps; Ilotycin; Mephamycin; Pantomicina; Propiocine; R-P Mycin; Robimycin; Sansac; Stiemycin; Torlamicina; Wemid; Erythro; (-)-ERYTHROMYCIN; 114-07-8; Abboticin; Abomacetin; Akne-Mycin; Benzamycin; Dotycin; Dumotrycin; E-Base; E-Glades; E-Mycin; E-Solve 2; Emgel; Eritrocina; Eritromicina; Ery-Tab; Eryacne; Eryc 125; Eryc Sprinkles; 643-22-1; Abboticine; Bristamycin; CCRIS 1504; Dowmycin E; EINECS 211-396-1; ERYTHROMYCIN STEARATE; ETHRIL 500
Click to Show/Hide
|
||||
Status |
Approved
|
||||
Structure |
|
||||
3D MOL
|
|||||
Formula |
C55H103NO15
|
||||
InChI |
1S/C37H67NO13.C18H36O2/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26;1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3;2-17H2,1H3,(H,19,20)/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-;/m1./s1
|
||||
InChIKey |
YAVZHCFFUATPRK-YZPBMOCRSA-N
|
||||
PubChem CID | |||||
INTEDE Drug ID |
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Cytochrome P450 1B1 (CYP1B1)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Erythromycin stearate. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Erythromycin stearate through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [1], [2] | ||
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Erythromycin stearate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Erythromycin stearate through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [2], [3] | ||
References